Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics is well positioned to benefit from the CSL Plasma agreement, which appears to validate its competitiveness in Plasma and could meaningfully expand revenue if CSL transitions across its current U.S. centers by end of calendar year 2027. The opportunity is attractive because CSL’s U.S. business contributed about $155 million in FY24, while Haemonetics has already shown strong operating leverage through FY2027 guidance for $1.400 billion-$1.441 billion in sales, 50-100 bps of adj. EBIT margin expansion, and ~80% FCF conversion. Beyond Plasma, the company’s mix is tilting toward higher-margin Hospital and MedSurg businesses, supported by recent growth in Plasma, a return to growth in Interventional Technologies, and continued gains from new products and disposables.

Haemonetics is facing a more cautious outlook because the business still depends on execution across new and existing Interventional Technologies products while also exposed to variable interventional cardiology and electrophysiology procedure volumes, leaving growth more fragile than its high-level narrative suggests. Competition in Plasma, the possible disruption from recombinant therapies or other treatments that could reduce demand for plasma-derived therapies, tariffs, and cybersecurity risks all create meaningful downside to revenue durability and operating consistency. Even with solid and increasing operating margins and a strong market presence, the need to sustain sales growth through new products and potential M&A makes the long-term thesis more dependent on flawless execution than the current setup appears to justify.